CEL-SCI (CVM) reports a Q1 loss of $0.02, in-line with estimates and even with a loss of $0.02 reported for Q1 2012. Net losses were $2.3M versus losses of $4.2M during the prior year period. R&D expenses increased by 25% Y/Y, largely due to the increased level of activity associated with conducting Phase III clinical studies. Shares -0.5% AH.
CEL-SCI (CVM) reports a Q1 loss of $0.02, in-line with estimates and even with a loss of $0.02...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs